Table 3.
Immunogenicity and efficacy of rabies vaccines in mice
| Live Attenuated RABV PBV | ERAg333a | Placebo | Commercial Vaccine | Inactivated RABV PBV | |||||
|---|---|---|---|---|---|---|---|---|---|
| Dilution | 10−1 | 10−2 | 10−3 | 10−2 | None | None | None | 10−1 | 10−2 |
| Titer | 6.8b | 5.7 | 4.4 | 7.9 | NAc | NA | NA | NA | NA |
| Load | NDd | ND | ND | ND | 300e | 620 | 350 | 34 | 2.3 |
| GMT day 14f | 0.28g | 0.19 | 0.24 | 0.42 | <0.05 | 0.092 | 0.096 | 0.077 | <0.05 |
| SD day14h | ±0.49g | ±0.68 | ±0.94 | ±0.97 | ±0.0097 | ±0.41 | ±0.10 | ±0.24 | ±0.016 |
| GMT day 30f | 1.8g | 0.96 | 1.7 | 0.84 | <0.05 | 0.58 | 0.36 | 0.15 | 0.067 |
| SD day 30h | ±2.4 g | ±15 | ±2.9 | ±1.9 | ±0.015 | ±1.9 | ±1.4 | ±0.57 | ±0.12 |
| Seroconversioni | 90%j | 100%j | 100% | 90% | 0% | 90% | 90% | 70%j | 30% |
| Survivalk | 100%j | 100% | 100% | 100% | 22% | 100% | 100% | 100% | 80%l |
a
Parent strain for both live attenuated and inactivated vaccines; generated by reverse genetics.
b
Log10 ffu in 0.1 ml dose.
c
Not applicable (NA); cannot be determined for inactivated vaccines.
d
Not determined (ND).
e
μg of total protein in 0.1 ml dose.
f
Geometric mean titer (GMT) of rabies virus neutralizing antibodies.
g
IU/ml.
h
Standard deviation (SD) of rabies virus neutralizing antibody titers.
i
Percent with >0.05 IU/ml titer on day 30; Group size =10 except placebo n=9.
j
p<0.01 compared to placebo using chi-square test with a 95% confidence interval.
k
Group size =10 except placebo n=9.
l
p<0.05 compared to placebo using chi-square test with a 95% confidence interval.